← Who reports today · Health Care
How AbbVie (ABBV) makes money: Q3 2026 revenue breakdown
Net earnings attributable to AbbVie Inc.
$4,218M
up ×23 y/y
Net revenues
$17,404M
up 10.3% y/y
Operating earnings
$6,267M
up 229% y/y
Next report
~ Feb 3
not announced yet
The quarter in brief
AbbVie's Q3 2026 net revenues rose 10.3% to $17,404M, with immunology at $9,165M (+16.3%) and neuroscience at $3,389M (+19.4%). GAAP net earnings were $4,218M against $186M a year earlier, with acquired IPR&D and milestones at $216M against $2,680M.
Key growth driver: Skyrizi — the largest product line: $5,776M, +22.7% y/y. · by the Q3 2026 report
How does AbbVie make money?
AbbVie brought in $17.4 billion of revenue in Q3 2026, up 10.3% year over year. The largest source was Immunology: $9.16 billion, or 53% of the total, followed by Neuroscience ($3.39B, 19%) and Oncology ($1.70B, 10%); other lines add the remaining 18%. Net income for the quarter was $4.22 billion.
Revenue by source, Q3 2026
- Immunology$9.16B · 53% · +16.3%
- Neuroscience$3.39B · 19% · +19.4%
- Oncology$1.70B · 10% · +0.8%
- Aesthetics$1.18B · 7% · −1.4%
- All other (remainder)$1.01B · 6%
- Other Key Products$965M · 6% · −4.1%
Shares of $17.4B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
All figures in $M.
| Line item | Amount and change |
|---|---|
| Skyrizi | $5,776 · +22.7% |
| Rinvoq | $2,706 · +23.9% |
| Humira | $683 · −31.2% |
| Vraylar | $1,068 · +14.3% |
| Botox Therapeutic | $1,080 · +9.8% |
| Ubrelvy | $449 · +26.9% |
| Qulipta | $398 · +38.2% |
| Vyalev | $286 · >100% |
| Other Neuroscience | $108 · −23.9% |
| Venclexta | $803 · +10.7% |
| Imbruvica | $522 · −26.1% |
| Elahere | $224 · +31.0% |
| Epkinly | $108 · +57.7% |
| Other Oncology | $39 · >100% |
| Botox Cosmetic | $669 · +4.9% |
| Juvederm Collection | $222 · −11.9% |
| Other Aesthetics | $285 · −6.0% |
| Mavyret | $265 · −15.1% |
| Creon | $361 · −2.2% |
| Linzess | $339 · +4.2% |
| Immunology | $9,165 · +16.3% |
| Neuroscience | $3,389 · +19.4% |
| Oncology | $1,696 · +0.8% |
| Aesthetics | $1,176 · −1.4% |
| Other Key Products | $965 · −4.1% |
| All other (remainder) | $1,013 |
| Net revenues | $17,404 · +10.3% |
| Cost of products sold | $4,285 · −19.2% |
| Gross profit | $13,119 · +25.3% |
| Other operating income | $18 · vs $0 |
| Selling, general and administrative | $4,087 · +14.5% |
| Research and development | $2,567 · +10.7% |
| Acquired IPR&D and milestones | $216 · −91.9% |
| Operating earnings | $6,267 · +229% |
| Interest expense, net | $700 · +4.9% |
| Other expense, net | $738 · +41.1% |
| Earnings before income tax expense | $4,829 · +576% |
| Income tax expense | $609 · +15.8% · 12.6% effective rate |
| Net earnings attributable to noncontrolling interest | $2 · vs $2 |
| Net earnings attributable to AbbVie Inc. | $4,218 · ×23 · $2.37/sh · 24.2% margin |
Verdict: AbbVie's Q3 2026 net revenues rose 10.3% to $17,404M, with immunology at $9,165M (+16.3%) and neuroscience at $3,389M (+19.4%). GAAP net earnings were $4,218M against $186M a year earlier, with acquired IPR&D and milestones at $216M against $2,680M.
AbbVie raised its 2026 adjusted diluted EPS guidance from $13.76 - $13.96 to $13.95 - $13.99, including a $0.69 per share unfavorable impact from acquired IPR&D and milestones incurred through Q3. The quarterly dividend rises 5.2% from $1.73 to $1.82 per share, beginning with the dividend payable on February 16, 2027. For the nine months, net revenues were $49,396 million and diluted EPS was $4.79 versus $1.34.
Source and notation
y/y for products, portfolios and net revenues is reported, as in the company's Key Product Revenues table (not operational). All other (remainder) = net revenues minus the five portfolios of that table. Gross profit = net revenues minus cost of products sold. Imbruvica international and Epkinly U.S. revenues reflect profit sharing. Source: AbbVie press release, 8-K EX-99.1 of 10/30/2026 (SEC EDGAR).
Open as an image: AbbVie (ABBV), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “AbbVie (ABBV) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/abbv. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/abbv"><img src="https://whoreportstoday.com/t/abbv/img/abbvie-abbv-earnings-sankey.png" alt="AbbVie (ABBV) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/abbv">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/abbv/img/abbvie-abbv-earnings-sankey.png
<a href="https://whoreportstoday.com/t/abbv">AbbVie (ABBV) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Immunology grew 16.3% to $9,165M: Skyrizi $5,776M (+22.7%) and Rinvoq $2,706M (+23.9%), while Humira fell 31.2% to $683M.
- Neuroscience rose 19.4% to $3,389M: Botox Therapeutic $1,080M (+9.8%), Vraylar $1,068M (+14.3%), Ubrelvy $449M (+26.9%), Qulipta $398M (+38.2%).
- Oncology grew 0.8% to $1,696M: Venclexta $803M (+10.7%) and Elahere $224M (+31.0%), Imbruvica $522M (−26.1%). Aesthetics fell 1.4% to $1,176M: Botox Cosmetic +4.9%, Juvederm Collection −11.9%.
- $1,013M of net revenues is not itemized in the company's product table; the chart shows it as one remainder line, without y/y.
- Gross margin was 75.4%. The GAAP operating margin was 36.0% against about 12.1% a year earlier; acquired IPR&D and milestones were $216M against $2,680M, cost of products sold $4,285M against $5,304M.
- Other expense, net rose to $738M from $523M, including an $829M change in fair value of contingent consideration against $776M.
- The GAAP tax rate was 12.6% against 73.7% in Q3 2025: income tax expense of $609M on pre-tax earnings of $4,829M.
- Weighted-average diluted shares were 1,772 million in both quarters. Diluted EPS was $2.37 against $0.10, adjusted diluted EPS $3.82 against $1.86.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Robert A. MichaelChairman of the Board and Chief Executive Officer [1]
- Scott T. ReentsExecutive Vice President, Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- AbbViesince 2012
- Chief Executive Officernow
- Vice President, Controller2017–2018
- Vice President, Treasurer2015–2016
- Vice President, Controller, Commercial Operations2013–2015
- Vice President, Financial Planning and Analysis2012–2013
- Abbott1993–2012
- Division Controller, Nutrition Supply Chain2010–2012
- Various positions1993
Source: SEC EDGAR: 10-K annual report, 2026-02-20 · as of 10/21/2026
- AbbViesince 2013
- Executive Vice President, Chief Financial Officernow
- Senior Vice President, Chief Financial Officer2022
- Vice President, Tax and Treasury2019–2022
- Vice President, Tax2013–2019
- Abbott2008Various positions
Source: SEC EDGAR: 10-K annual report, 2026-02-20 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-11-03 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-11-03 · SEC EDGAR · 11/18/2026
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. · Text: Wikipedia, CC BY-SA 4.0, abridged
AbbVie produces drugs to treat a wide range of medical issues. Market share (US pharma & biotech): ≈9% by TTM revenue.
Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | EPS (non-GAAP) $13.95–13.99 (raised) | revenue $61.2BEPS (GAAP) $2.36 | — |
Same quarter a year ago (ended December 31, 2025): revenue $16.62B, EPS (GAAP) $1.02
How we calculate
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 30, 2026); every figure is checked against the release text.
ABBV earnings history: past report dates
| Oct 30, 2026 Fri | 7:51 ambefore market open | Sep 30, 2026 | $17.4B+10% y/y | $2.37 |
| Jul 31, 2026 Fri | 7:51 ambefore market open | Jun 30, 2026 | $17.0B+10% y/y | $2.03+290% y/y |
| Apr 29, 2026 Wed | 7:50 ambefore market open | Mar 31, 2026 | $15.0B+12% y/y | $0.39−46% y/y |
| Feb 4, 2026 Wed | 7:54 ambefore market open | Dec 31, 2025 | $16.6B+10% y/y | $1.02 |
| Oct 31, 2025 Fri | 7:51 ambefore market open | Sep 30, 2025 | $15.8B+9% y/y | $0.10−89% y/y |
| Jul 31, 2025 Thu | 7:48 ambefore market open | Jun 30, 2025 | $15.4B+7% y/y | $0.52−32% y/y |
| Apr 25, 2025 Fri | 7:48 ambefore market open | Mar 31, 2025 | $13.3B+8% y/y | $0.72−6% y/y |
| Jan 31, 2025 Fri | 7:42 ambefore market open | Dec 31, 2024 | $15.1B+6% y/y | −$0.02 |
| Oct 30, 2024 Wed | 7:43 ambefore market open | Sep 30, 2024 | $14.5B+4% y/y | $0.88−12% y/y |
| Jul 25, 2024 Thu | 7:41 ambefore market open | Jun 30, 2024 | $14.5B+4% y/y | $0.77−32% y/y |
| Apr 26, 2024 Fri | 7:43 ambefore market open | Mar 31, 2024 | $12.3B+1% y/y | $0.77+492% y/y |
| Feb 2, 2024 Fri | 7:51 ambefore market open | Dec 31, 2023 | $14.3B−5% y/y | $0.46−67% y/y |
Show all 12 reports since 2024Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
AbbVie: 15-year financials
| 2025 | 61,160 | 15,075 | 4,226 | 17,816 | 11,657 |
| 2024 | 56,334 | 9,137 | 4,278 | 17,832 | 11,025 |
| 2023 | 54,318 | 12,757 | 4,863 | 22,062 | 10,539 |
| 2022 | 58,054 | 18,117 | 11,836 | 24,248 | 10,043 |
| 2021 | 56,197 | 17,924 | 11,542 | 21,990 | 9,261 |
| 2020 | 45,804 | 11,363 | 4,616 | 16,790 | 7,716 |
| 2019 | 33,266 | 12,983 | 7,882 | 12,772 | 6,366 |
| 2018 | 32,753 | 6,383 | 5,687 | 12,789 | 5,580 |
| 2017 | 28,216 | 9,545 | 5,309 | 9,431 | 4,107 |
| 2016 | 25,638 | 9,340 | 5,953 | 6,562 | 3,717 |
| 2015 | 22,859 | 7,537 | 5,144 | 7,003 | 3,294 |
| 2014 | 19,960 | 3,411 | 1,774 | 2,937 | 2,661 |
| 2013 | 18,790 | 5,664 | 4,128 | 5,776 | 2,555 |
| 2012 | 18,380 | 5,817 | 5,275 | 6,012 | — |
| 2011 | 17,444 | 3,620 | 3,433 | 5,891 | — |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.
AbbVie: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 133,960 | −3,270 | 67,002 | 5,229 | 29,062 | 43,289 |
| 2024 | 135,161 | 3,325 | 66,841 | 5,524 | 25,582 | 38,749 |
| 2023 | 134,711 | 10,360 | 59,245 | 12,814 | 33,002 | 37,841 |
| 2022 | 138,805 | 17,254 | 63,129 | 9,201 | 28,463 | 29,538 |
| 2021 | 146,529 | 15,408 | 75,976 | 9,746 | 27,928 | 35,194 |
| 2020 | 150,565 | 13,076 | 84,982 | 8,449 | 24,173 | 28,661 |
| 2019 | 89,115 | −8,172 | 67,233 | 39,924 | 49,519 | 15,585 |
| 2018 | 59,352 | −8,446 | 40,310 | 7,289 | 16,945 | 17,239 |
| 2017 | 70,786 | 5,097 | 37,368 | 9,303 | 21,223 | 16,641 |
| 2016 | 66,099 | 4,636 | 36,842 | 5,100 | 16,187 | 9,781 |
| 2015 | 53,050 | 3,945 | 31,671 | 8,399 | 16,314 | 10,894 |
| 2014 | 27,513 | 1,742 | 14,977 | 8,348 | 16,081 | 11,393 |
| 2013 | 29,198 | 4,492 | 14,723 | 9,595 | 17,848 | 6,879 |
| 2012 | 27,008 | −350 | 15,672 | 5,901 | 15,354 | 6,776 |
| 2011 | — | — | — | 27 | — | — |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 14,871 | 13,812 | +1,059 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 574 | 559 | |
| · incl. stock-based comp (non-cash)share-based compensation | 770 | 798 | |
| Capexpurchases of property & equipment | −888 | −885 | −3 |
| Free cash flow ≈operating cash flow − capex | 13,983 | 12,927 | +1,056 |
| Investing activities, netcapex, acquisitions, securities | −11,986 | −5,180 | −6,806 |
| · incl. acquisitionsbusinesses net of cash acquired | −10,594 | −204 | −10,390 |
| Financing activities, netdebt, buybacks, dividends | 2,685 | −8,558 | +11,243 |
| · incl. buybacksrepurchases of common stock | −1,503 | −977 | −526 |
| · incl. dividends paid | −9,227 | −8,746 | −481 |
| FX effect on cash | −25 | 31 | −56 |
| Net change in cash | 5,545 | 105 | +5,440 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: −$4.6B (−3.1% of total assets). Other S&P 500 companies with negative equity →
Corporate governance
2/2good
- Mar 2026Per the 2026 proxy, common stock is AbbVie's only voting security, with one vote per share. sec.gov ↗
- Dec 2025Diluted shares rose 6% over 2020–2025; SBC of $0.96B = 1.6% of $61.2B revenue (2025 10-K). data.sec.gov ↗
2 more facts and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Dec 2025The per-share dividend has risen every year: $4.84 (2020) → $6.65 (2025). data.sec.gov ↗
- Feb 2026The Legal Proceedings section of the 2025 10-K lists no shareholder class actions or SEC investigations — only product liability and antitrust cases. sec.gov ↗
Scoring: 2.0, no deductions: single share class, dilution +6% over 5 years (<10%), SBC 1.6% of revenue, dividend raised every year, no shareholder suits or SEC cases in the 10-K
- Share classes
- Single class: common stock is the only voting security, one share = one vote (2026 proxy).
- Dilution
- Diluted shares +6% over 2020–2025 (mostly the tail of the stock component of the 2020 Allergan deal, at market), SBC 1.6% of revenue — below thresholds.
- Disclosure
- Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
- Dividends
- Dividend raised every year since the 2013 spin-off ($4.84 → $6.65 over 2020–2025, XBRL).
- Lawsuits & regulators
- The 2025 10-K lists only product liability/antitrust suits (Humira, Niaspan, Allergan implants); no shareholder class actions or SEC cases.
- Related parties
- Committee approval policy for related-party transactions; no material transactions disclosed in the 2026 proxy.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
AbbVie (ABBV) earnings: FAQ
How does AbbVie make money?
AbbVie brought in $17.4 billion of revenue in Q3 2026, up 10.3% year over year. The largest source was Immunology: $9.16 billion, or 53% of the total, followed by Neuroscience ($3.39B, 19%) and Oncology ($1.70B, 10%); other lines add the remaining 18%. Net income for the quarter was $4.22 billion.
When is ABBV's next earnings date?
We have not yet seen an announcement of the date from AbbVie (ABBV). Based on last year's report on Feb 4, 2026, the next report is expected around Feb 3, 2027.
What time does ABBV report earnings?
AbbVie usually reports before market open: its latest results release was filed with the SEC at 7:51 am ET on Oct 30, 2026.
When did ABBV last report earnings?
AbbVie reported Q3 2026 results on Oct 30, 2026.
What has AbbVie guided for FY2026?
Company guidance for FY2026: EPS (non-GAAP) $13.95–13.99 (raised). A year ago (FY2025): revenue $61.2B, EPS (GAAP) $2.36. Source: the company's earnings release (Form 8-K filed Oct 30, 2026).
Where can I find AbbVie's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to ABBV's filings; this page breaks the latest report down in a Sankey chart.
What was ABBV's net income in Q3 2026?
AbbVie reported net income of $4,218M for Q3 2026 (×23 year over year), under US GAAP.
Does AbbVie pay dividends?
Yes. In 2025, AbbVie paid $11,657M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has AbbVie's revenue changed since 2011?
Per its 10-K filings, revenue grew 3.5x: $17,444M in 2011 and $61,160M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · BDX · Q4 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · all reports